- 25027874OWN - NLMSTAT- MEDLINEDA  - 20140917DCOM- 20141118LR  - 20150324IS  - 1941-3297 (Electronic)IS  - 1941-3289 (Linking)VI  - 7IP  - 5DP  - 2014 SepTI  - Bridge-to-decision therapy with a continuous-flow external ventricular assist      device in refractory cardiogenic shock of various causes.PG  - 799-806LID - 10.1161/CIRCHEARTFAILURE.113.000271 [doi]AB  - BACKGROUND: Mortality for refractory cardiogenic shock remains high. In this      patient cohort, there have been mixed results in mechanical circulatory support      device use as a bridge-to-decision therapy. We evaluated a continuous-flow      external ventricular assist device (VAD), CentriMag VAD (Thoratec Corp.,      Pleasanton, CA), in patients with various causes of refractory cardiogenic shock.      METHODS AND RESULTS: This is a retrospective review of adult patients who      underwent surgical CentriMag VAD insertion as bridge-to-decision therapy. From      January 2007 through June 2012, 143 patients received CentriMag VAD. The cause of      refractory cardiogenic shock was failure of medical management in 71 patients,      postcardiotomy shock in 37, graft failure post-heart transplantation in 22, and      right ventricular failure post-implantable left VAD in 13. Mean age was 52+/-16      years, and 71% were in INTERMACS (Interagency Registry for Mechanically Assisted       Circulatory Support) profile 1. Among 158 device runs, device configuration was      BiVAD in 67%, isolated right VAD in 26%, and isolated left VAD in 8%. Median      duration of support was 14 days (interquartile range, 8-26). Survival was 69% at       30 days and 49% at 1 year. The next destination after the CentriMag VAD was      myocardial recovery in 30%, device exchange to an implantable VAD in 15%, and      heart transplantation in 18%. The failure of medical management and the graft      failure post-heart transplantation groups had higher 30-day survival compared      with the postcardiotomy shock group. Major bleeding events occurred in 33% and      cerebrovascular accidents in 14%. There was no CentriMag pump failure or      thrombosis. CONCLUSIONS: Bridge-to-decision therapy with CentriMag VAD is      feasible in a variety of refractory cardiogenic shock settings. Patients with      postcardiotomy shock have inferior survival.CI  - (c) 2014 American Heart Association, Inc.FAU - Takayama, HirooAU  - Takayama HAD  - From the Departments of Surgery (H.T., L.S., B.K., L.K.T., T.O., S.C., Z.K.,      Y.N.) and Medicine (N.U., P.C., D.M.M., U.P.J.), Columbia University Medical      Center, New York, NY. hirofu2@hotmail.com.FAU - Soni, LoriAU  - Soni LAD  - From the Departments of Surgery (H.T., L.S., B.K., L.K.T., T.O., S.C., Z.K.,      Y.N.) and Medicine (N.U., P.C., D.M.M., U.P.J.), Columbia University Medical      Center, New York, NY.FAU - Kalesan, BinduAU  - Kalesan BAD  - From the Departments of Surgery (H.T., L.S., B.K., L.K.T., T.O., S.C., Z.K.,      Y.N.) and Medicine (N.U., P.C., D.M.M., U.P.J.), Columbia University Medical      Center, New York, NY.FAU - Truby, Lauren KAU  - Truby LKAD  - From the Departments of Surgery (H.T., L.S., B.K., L.K.T., T.O., S.C., Z.K.,      Y.N.) and Medicine (N.U., P.C., D.M.M., U.P.J.), Columbia University Medical      Center, New York, NY.FAU - Ota, TakeyoshiAU  - Ota TAD  - From the Departments of Surgery (H.T., L.S., B.K., L.K.T., T.O., S.C., Z.K.,      Y.N.) and Medicine (N.U., P.C., D.M.M., U.P.J.), Columbia University Medical      Center, New York, NY.FAU - Cedola, SophiaAU  - Cedola SAD  - From the Departments of Surgery (H.T., L.S., B.K., L.K.T., T.O., S.C., Z.K.,      Y.N.) and Medicine (N.U., P.C., D.M.M., U.P.J.), Columbia University Medical      Center, New York, NY.FAU - Khalpey, ZainAU  - Khalpey ZAD  - From the Departments of Surgery (H.T., L.S., B.K., L.K.T., T.O., S.C., Z.K.,      Y.N.) and Medicine (N.U., P.C., D.M.M., U.P.J.), Columbia University Medical      Center, New York, NY.FAU - Uriel, NirAU  - Uriel NAD  - From the Departments of Surgery (H.T., L.S., B.K., L.K.T., T.O., S.C., Z.K.,      Y.N.) and Medicine (N.U., P.C., D.M.M., U.P.J.), Columbia University Medical      Center, New York, NY.FAU - Colombo, PaoloAU  - Colombo PAD  - From the Departments of Surgery (H.T., L.S., B.K., L.K.T., T.O., S.C., Z.K.,      Y.N.) and Medicine (N.U., P.C., D.M.M., U.P.J.), Columbia University Medical      Center, New York, NY.FAU - Mancini, Donna MAU  - Mancini DMAD  - From the Departments of Surgery (H.T., L.S., B.K., L.K.T., T.O., S.C., Z.K.,      Y.N.) and Medicine (N.U., P.C., D.M.M., U.P.J.), Columbia University Medical      Center, New York, NY.FAU - Jorde, Ulrich PAU  - Jorde UPAD  - From the Departments of Surgery (H.T., L.S., B.K., L.K.T., T.O., S.C., Z.K.,      Y.N.) and Medicine (N.U., P.C., D.M.M., U.P.J.), Columbia University Medical      Center, New York, NY.FAU - Naka, YoshifumiAU  - Naka YAD  - From the Departments of Surgery (H.T., L.S., B.K., L.K.T., T.O., S.C., Z.K.,      Y.N.) and Medicine (N.U., P.C., D.M.M., U.P.J.), Columbia University Medical      Center, New York, NY.LA  - engGR  - T32 HL007854/HL/NHLBI NIH HHS/United StatesPT  - Comparative StudyPT  - Journal ArticleDEP - 20140715PL  - United StatesTA  - Circ Heart FailJT  - Circulation. Heart failureJID - 101479941SB  - IMMH  - Cardiac Surgical Procedures/adverse effectsMH  - Feasibility StudiesMH  - FemaleMH  - Follow-Up StudiesMH  - Heart Failure/*complications/mortality/physiopathologyMH  - *Heart-Assist DevicesMH  - HumansMH  - MaleMH  - Middle AgedMH  - New York/epidemiologyMH  - PrognosisMH  - Prosthesis DesignMH  - Retrospective StudiesMH  - Shock, Cardiogenic/complications/mortality/*therapyMH  - Survival Rate/trendsPMC - PMC4369383MID - NIHMS651971OID - NLM: NIHMS651971OID - NLM: PMC4369383OTO - NOTNLMOT  - heart-assist devicesOT  - shock, cardiogenicEDAT- 2014/07/17 06:00MHDA- 2014/11/19 06:00CRDT- 2014/07/17 06:00PHST- 2014/07/15 [aheadofprint]AID - CIRCHEARTFAILURE.113.000271 [pii]AID - 10.1161/CIRCHEARTFAILURE.113.000271 [doi]PST - ppublishSO  - Circ Heart Fail. 2014 Sep;7(5):799-806. doi: 10.1161/CIRCHEARTFAILURE.113.000271.      Epub 2014 Jul 15.